MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified (Q34000188)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

6

object named as

Xin-Lan Luo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

3

object named as

Dong-Lan Luo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Li-Xu Yan

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yan-Hui Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fen Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yu Cheng

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jie Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jie Cheng

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Heng-Guo Zhuang

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

4 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

e104068

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

4 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MYCtranslocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Impact of immunochemotherapy on prognostic factors in diffuse large B-cell lymphoma patients]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low incidence of BCL-6 gene alterations for diffuse large B-cell lymphomas in Taiwan Chinese

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0104068

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2014PLoSO...9j4068Y

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34000188&oldid=2041304581"